ATI-1777: Promising Topical Jak1/3 Inhibitor for Atopic Dermatitis without Systemic Effects
The following is a summary of "ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201," published in the March 2024 issue of...